Predictive Biosciences is a molecular diagnostics company headquartered in Lexington, MA. Launched in 2006 with a $10 million Series A financing, the company was jointly founded by leading healthcare investors, experienced entrepreneurs, and internationally-renowned scientists in the areas of tumor growth, tumor angiogenesis, and cancer markers. Predictive Biosciences possesses an extensive IP portfolio – including 18 issued and pending US patents – and deep in-house expertise in proteomics, diagnostics, oncology, and tumor biomarkers.
Leveraging its portfolio of patented biomarkers and clinical algorithms, Predictive Biosciences is pioneering novel diagnostic assays for informed cancer management™. Predictive seeks to significantly improve care and reduce healthcare costs for cancer patients by personalizing diagnostic workups and clinical interventions.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 10/01/08 | Series B | 21.75M | New Enterprise Associates, Kaiser Permanente Ventures | Unknown |
People
Peter Klemm (CEO, President)
Anthony Shuber (CTO, Co-Founder)
Vikram Lamba (CFO)
Mara Aspinall (President, CEO)
Marsha Moses (Board member)
View more details about all 6 people at Predictive Biosciences